For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
17
views
6
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      486
      similar
       All similar
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Influence of Latanoprost on the Corneal Epithelial Barrier Function in Glaucoma Patients

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aim: To evaluate the influence of topically administered latanoprost, a prostaglandin F<sub>2α</sub> analog, on the corneal epithelial barrier function. Patients and Methods: Twenty-four patients suffering from a glaucoma were enrolled. Ten patients without prior topical antiglaucoma medication received topical latanoprost (0.005%, once daily) for 30 days (monotherapy group); 14 patients receiving topical antiglaucoma medication also received latanoprost (0.005%, once daily) for 180 days (combination treatment group). Before and 30 days after treatment (monotherapy group) and before and 30 and 180 days after treatment (combination group), the corneal epithelial barrier function was measured by a fluorophotometric technique. Results: The fluorescein uptakes in the monotherapy group were 54.6 ± (SE) 7.5 and 57.1 ± 11.0 ng/ml before and 30 days after treatment, respectively (p = 0.81). In the combination group, the uptakes were 101.0 ± 18.3 and 118.9 ± 25.9 ng/ml (p = 0.38) and 93.4 ± 17.5 ng/ml (p = 0.58) before and 30 and 180 days after treatment, respectively. Conclusion: The corneal epithelial barrier function remained intact following the instillation of latanoprost in both groups.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Anterior uveitis associated with latanoprost.

          Robert Fechtner, Albert S. Khouri, Thom Zimmerman … (1998)
          To report the association of anterior uveitis with the use of latanoprost. We studied four patients with complicated open-angle glaucoma who had anterior uveitis associated with the use of latanoprost. The uveitis was unilateral and occurred only in the eye receiving latanoprost in three patients. In one patient, latanoprost was used in both eyes, and the uveitis was bilateral. Four of five eyes had a history of prior inflammation and/or prior incisional surgery. All patients were rechallenged with the drug. The uveitis improved after cessation of latanoprost with or without topical corticosteroids. It recurred after rechallenging with latanoprost in all eyes. There is a possible association between latanoprost and anterior uveitis. Topical prostaglandin analogs may be relatively contraindicated in patients with a history of uveitis or prior ocular surgery. This association may also be possible in eyes that have not had previous uveitis or incisional surgery.
          Article 0 comments Cited 31 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Latanoprost: experience of 2-year treatment in Scandinavia.

            A. Alm, I Widengård (2000)
            The aim of the study was to assess efficacy and side effects of latanoprost during two years of treatment.
            Article 0 comments Cited 7 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Effect of Beta-Blocker Eyedrops on Corneal Epithelial Barrier Function

              Akiko Niiya, Norihiko Yokoi, Yasuhiro Matsumoto … (2000)
              To investigate the long-term effect of a topically applied β-blocker on human corneal epithelium, the corneal epithelial barrier function and the superficial cell area of the corneal epithelium were evaluated. Seventeen normal healthy volunteers (without medication), 7 cataract patients (treated with pyrenoxine eyedrops) and 7 glaucoma or ocular hypertension patients (treated with 0.5% timolol maleate) were assigned to this study. The eyedrops had been used on a daily basis for at least 3 months. In the evaluation of corneal epithelial barrier function, fluorescein uptake was measured using a slitlamp fluorophotometer after application of 3 μl of 0.5% fluorescein for 10 min. In the evaluation of the superficial cell area, the central corneal epithelium was measured by tandem scanning confocal microscopy (TSCM). The healthy control and timolol groups were compared. Corneal fluorescein uptake in the healthy control, pyrenoxine and timolol groups was 20.3 ± 3.2, 21.5 ± 4.0 and 76.2 ± 30.0 ng/ml (mean ± standard error), respectively. There was a significantly higher fluorescein uptake in the timolol group compared to the pyrenoxine group (p = 0.0088) and the healthy control group (p = 0.0055). TSCM showed no significant difference in the superficial cell areas of the corneal epithelium between the healthy control and timolol groups. β-Blocker eyedrops decreased the corneal epithelial barrier function. Their application was not accompanied by any biomicroscopic change in the superficial cell area.
              Article 0 comments Cited 6 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (publisher-id): OPH
                Journal ID (nlm-ta): Ophthalmologica
                Journal ID (doi): 10.1159/issn.0030-3755
                Title: Ophthalmologica
                Publisher: S. Karger AG
                ISSN (Print): 0030-3755
                ISSN (Electronic): 1423-0267
                Publication date Subscription-year: 2002
                Publication date (Print): October 2002
                Publication date (Electronic): 08 November 2002
                Volume: 216
                Issue: 5
                Pages: 351-354
                Affiliations
                Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
                Article
                Publisher ID: 66180 Other ID: Ophthalmologica 2002;216:351–354
                DOI: 10.1159/000066180
                PubMed ID: 12424402
                SO-VID: 0ecf3adc-8f98-4bc0-99ae-8de7f0bd0a33
                Copyright © © 2002 S. Karger AG, Basel
                License:

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Date received : 25 January 2002
                Page count
                Figures: 2, References: 25, Pages: 4
                Categories
                Subject: Original Paper · Travail original · Originalarbeit

                ScienceOpen disciplines: Vision sciences,Ophthalmology & Optometry,Pathology
                Keywords: Beta-blocker,Isopropyl unoprostone,Fluorophotometry,Latanoprost,Corneal epithelial barrier function
                Data availability:
                ScienceOpen disciplines: Vision sciences, Ophthalmology & Optometry, Pathology
                Keywords: Beta-blocker, Isopropyl unoprostone, Fluorophotometry, Latanoprost, Corneal epithelial barrier function

                Comments

                Comment on this article

                scite_

                Similar content486

                See all similar

                Cited by3

                See all cited by

                Most referenced authors107

                See all reference authors